Immutep reports new data from phase 2 TACTI-002 trial

Latest News

Immutep (ASX:IMM) has announced new interim data from lung cancer patients in one of its key clinical trials.

The phase 2 TACTI-002 trial is studying the company's LAG-3 Candidate, eftilagimod alpha (efti), as a second-line treatment for patients with non-small cell lung cancer (NSCLC).

The new data was presented at the IASLC 2022 World Conference on Lung Cancer (WCLC 2022) in Australia.

The company said the data has revealed that encouraging efficacy results continue for patients in the trial.

Median Overall Survival (OS) from therapy with efti in combination with MSD's pembrolizumab is 9.7 months with 25 per cent of patients being progression-free at six months and 36.5 per cent alive at 18 months.

Immutep's Dr Frederic Triebel, said: “It is encouraging to see efti in combination with pembrolizumab continues to report promising antitumour and safety results in 2nd line NSCLC. In particular, efti in combination with pembrolizumab is demonstrating sustained survival compared with standard of care chemotherapy regimens, and favourable safety and tolerability. Of course, for patients with such advanced disease, having a chemo-free alternative could mean a very real difference to their quality of life.

“Furthermore, these results provide promising insights into how efti may provide a meaningful patient benefit in other PD-X refractory indications in the future,” he said.

TACTI-002 investigator Dr Martin Forster added, “The TACTI-002 trial is showing 36.5% of patients have survived for at least 18 months when receiving efti in combination with pembrolizumab. The median overall survival is 9.7 months which is a meaningful survival benefit, plus disease control and durability have also continued favourably as the trial has advanced. All these results support further clinical investigation of efti in combination with pembrolizumab in PD-X resistant NSCLC patients.”